Background
SUN Grades (2005) | |
Anterior chamber cells | Non-linear ordinal scale: 0 (no cells in examined field), 0.5+ (1–5 cells), 1+ (6–15), 2+ (16–25), 3+ (26–50), 4+ (> 50 cells in examined field) |
Anterior chamber flare | Non-linear ordinal scale from 0 (no clouding of view of anterior structures) to 4+ (intense fibrin deposition in anterior chamber) |
Vitreous haze | Non-linear ordinal scale from 0 (no clouding of view through vitreous) to 4 (unable to see through vitreous gel) |
MIGWUC outcome domains (2012) | |
Grade of activity in anterior chamber | Slit lamp exam (subjective measure of cells and flare) and laser photometry (objective measure of flare), and number of visits with active uveitis |
Visual acuity | Appropriate for age at testing |
Development of structural complications | Slit lamp examination for anterior structural complications Presence of high eye pressure or glaucoma (diagnostic protocol not clear) Slit lamp examination or imaging for posterior structural complications |
Quality of life |
Child Health Assessment Questionnaire
a
; Child Health Questionnaire
a
Pediatric Quality of life Inventory; Uveitis-specific quality of life instrumentb |
Overall uveitis related disability | Visual analog scale scoring undertaken by child, family, ophthalmologist or rheumatologist |
Social outcome | School absence |
Anti-inflammatory medication | Reduction in corticosteroid use |
Surgery | Yes / no |
Biomarkers | Research tools |
Main text
Methods
Identification of clinical trial registries
Review inclusion criteria
Selection of trials for review
Data extraction
Analyses
Results
Identification of interventional trials relevant to paediatric uveitis
Primary outcome characteristic | Details |
---|---|
Outcome structure |
Single, composite or multiple separate single measures
|
Outcome type |
Safety, efficacy or both
|
Dimension |
Visual function
|
Disease activity
| |
Use of anti-inflammatory medication
| |
Structural or functional sequelae of inflammation
| |
Vision related quality of life
| |
Other patient reported outcome measure
|
Characteristics of included trials
Outcome measure structure and type
Registry | Uveitisa | Childhood uveitisa | JIAa |
---|---|---|---|
National registries | |||
Australian New Zealand Clinical Trials Registry (ANZCTR) | 20 | 2 | 18 |
Brazilian Clinical Trials Registry (ReBec) | 0 | 0 | 1 |
Chinese Clinical Trial Registry (ChiCTR) | 5 | 2 | 0 |
Clinical Research Information Service (CRiS), Republic of Korea | 0 | 0 | 0 |
Clinical Trials Registry - India (CTRI) | 15 | -b | 2 |
Cuban Public Registry of Clinical Trials (RPCEC) | 4 | 0 | 1 |
German Clinical Trials Register (DRKS) | 19 | -b | 54 |
Iranian Registry of Clinical Trials (IRCT) | 33 | 1 | 0 |
Japan Primary Registries Network (JPRN) | 91 | 6 | 16 |
Thai Clinical Trials Registry (TCTR) | 2 | 0 | 0 |
The Netherlands National Trial Register (NTR) | 4 | 0 | 5 |
Sri Lanka Clinical Trials Registry (SLCTR) | 0 | 0 | 0 |
U.S. National Institutes of Health: USA only | 177 | 63 | 82 |
International registries | |||
U.S. National Institutes of Health: International | 328 | 107 | 192 |
ISCTRP | 302 | 59 | 217 |
Pan African Clinical Trial Registry (PACTR) | 0 | 0 | 0 |
EU Clinical Trials Register (EU-CTR) | 78 | 9 | 61 |
Total individual studies (excluding duplications) | 271 | 249 | 649 |
Outcome measure quality
Anterior (n = 20) | Anterior & intermediate (n = 7) | Posterior (n = 5) | Any site (n = 24) | Total (n = 57) | |
---|---|---|---|---|---|
Uveitis related primary outcome | 18 | 4 | 3 | 17 | 42 |
Safety only |
0
|
0
|
0
|
0
|
0
|
Single efficacy |
9
|
2
|
1
|
4
|
16
|
Multiple separate efficacy |
7
|
2
|
2
|
11
|
22
|
Composite efficacy |
2
|
0
|
0
|
2
|
4
|
Time to outcome measure in years (IQR) | 0.04–0.5 | 0.4–3 | 1–2.5 | 0.5–2 | 0.2–2 |
Activity | 20 | 8 | 5 | 18 | 47 |
ACC inactive SUN grade |
7
|
3
|
–
|
4
|
–
|
ACC 2 step change SUN grade |
1
|
0
|
–
|
3
|
–
|
Objective assessment AC Flare |
1
|
1
|
0
|
0
|
–
|
Other AC assessment |
11
|
4
|
2
|
1
|
–
|
Vitreous CC zero |
–
|
3
|
0
|
1
|
–
|
Vitreous 2 step change SUN grade |
–
|
0
|
0
|
2
|
–
|
Vitreous CC reduction |
–
|
0
|
2
|
3
|
–
|
Objective assessment vitreous |
–
|
0
|
0
|
0
|
–
|
Other vitreous assessment |
–
|
5
|
1
|
1
|
–
|
Macular oedema (MO) |
3
|
2
|
3
|
13
|
21
|
Objective assessment MO |
2
|
2
|
3
|
12
|
19
|
Use of topical steroids |
1
|
1
|
1
|
4
|
7
|
Use of systemic steroids |
0
|
2
|
1
|
4
|
7
|
Visual acuity | 4 | 1 | 3 | 14 | 21 |
Age appropriate measure |
0
|
1
|
1
|
6
|
8
|
Reproducible assessment of cataract | 0 | 0 | 0 | 0 | 0 |
Reproducible assessment of glaucoma | 0 | 0 | 0 | 0 | 0 |
Reproducible assessment of band keratopathy | 0 | 0 | 0 | 0 | 0 |
Vision related function | 1 | 0 | 0 | 2 | 3 |
Vision related quality of life | 1 | 0 | 2 | 0 | 3 |
Non-specific quality of life measure | 1 | 0 | 1 | 1 | 3 |
Validated for use in children |
0
|
0
|
0
|
0
|
0
|